/IRON
IRON Stock - Disc Medicine, Inc.
Healthcare|BiotechnologyNASDAQ
$80.04-11.50%
$10.40 (-11.50%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.20
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+50.4%upside
Target: $120.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IRON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$79.24 – $80.84
TARGET (TP)$120.40
STOP LOSS$73.64
RISK/REWARD1:6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.51
52W High$99.50
52W Low$30.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-322,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-129,720,000 | $-91,125,000 | $-47,475,000 | $-30,933,000 | $-34,040,000 |
| Net Income | $-109,357,000 | $-76,429,000 | $-46,827,000 | $-35,969,000 | $-40,837,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.96 | $-3.42 | $-45.05 | $-44.88 | $-27.02 |
Company Overview
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
3
20%
Buy / Outperform
11
73%
Hold / Neutral
1
7%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish1 Neutral/Bearish
Price Targets
$68
Average Target
↓ 15.0% Downside
Now
$36
Low
$68
Average
$125
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | Stifel | Resumed | Buy | $125 |
| July 21st 2025 | Truist | Initiation | Buy | $86 |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $85 |
| June 11th 2025 | Raymond James | Resumed | Strong Buy | $89 |
| February 27th 2025 | TD Cowen | Initiation | Buy | - |
| November 5th 2024 | Morgan Stanley | Upgrade | Overweight | $85 |
| November 4th 2024 | Raymond James | Upgrade | Strong Buy | $110← $66 |
| October 23rd 2024 | Jefferies | Initiation | Buy | $89 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| August 22nd 2024 | Wells Fargo | Initiation | Overweight | $75 |
| April 1st 2024 | Raymond James | Downgrade | Outperform | $40 |
| December 19th 2023 | Morgan Stanley | Downgrade | Equal Weight | $65← $56 |
| June 9th 2023 | Raymond James | Upgrade | Strong Buy | $75← $50 |
| June 7th 2023 | H.C. Wainwright | Initiation | Buy | $55 |
| May 17th 2023 | Raymond James | Initiation | Outperform | $50 |
Earnings History & Surprises
IRONBeat Rate
56%
Last 18 quarters
Avg Surprise
-3.0%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-1.77
Q4 2025
EPS Surprise History
Q1 24
-29.3%
$-0.97vs$-0.75
Q2 24
-9.0%
$-1.09vs$-1.00
Q3 24
+7.2%
$-1.03vs$-1.11
Q4 24
+9.2%
$-0.89vs$-0.98
Q1 25
+7.5%
$-0.98vs$-1.06
Q2 25
-3.0%
$-1.02vs$-0.99
Q3 25
-35.0%
$-1.58vs$-1.17
Q4 25
-19.6%
$-1.77vs$-1.48
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.71 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.48 | $-1.77 | -19.6% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.17 | $-1.58 | -35.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.99 | $-1.02 | -3.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-1.06 | $-0.98 | +7.5% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.98 | $-0.89 | +9.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.11 | $-1.03 | +7.2% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-1.00 | $-1.09 | -9.0% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.75 | $-0.97 | -29.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.75 | $-0.58 | +22.7% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.88 | $-0.74 | +15.9% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.62 | $-1.20 | -93.5% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.76 | $-1.22 | -60.5% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-5.90 | $-0.08 | +98.6% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-2.00 | $-1.60 | +20.0% | ✓ BEAT |
Q2 2022 | May 6, 2022 | $-3.01 | $-3.50 | -16.3% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-4.97 | $-4.10 | +17.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-4.73 | $-4.30 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-4.00 | $-3.80 | +5.0% | ✓ BEAT |
Latest News
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $109
📈 PositiveBenzinga•Dec 16, 2025, 02:56 PM
Reported Saturday, Disc Medicine Reports RALLY-MF DISC-0974 Data Showing Transfusion Independence In TD Low Patients And Reduced Transfusion Requirement In TD High Patients
📈 PositiveBenzinga•Dec 8, 2025, 09:31 AM
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $114
📈 PositiveBenzinga•Nov 10, 2025, 04:24 PM
Disc Medicine Q3 EPS $(1.77) Misses $(1.51) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:40 PM
Disc Medicine To Present Data On DISC-0974, DISC-3405 At American Society Of Hematology In Orlando
➖ NeutralBenzinga•Nov 3, 2025, 02:15 PM
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 12:28 PM•Also:
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115
📈 PositiveBenzinga•Oct 30, 2025, 06:04 PM
Disc Medicine Prices $250M Upsized Public Offering At $84 Per Share To Fund Bitopertin Commercialization And Pipeline Expansion
📈 PositiveBenzinga•Oct 21, 2025, 06:20 AM
Disc Medicine Accelerates Late-Stage Trials For Anemia And Blood Disorders Ahead Of Key 2026 Data, Targets 2025–2026 Milestones With FDA-Backed Bitopertin And Expanding Iron Regulation Pipeline
📈 PositiveBenzinga•Oct 20, 2025, 10:35 AM
Raymond James Maintains Strong Buy on Disc Medicine, Raises Price Target to $108
📈 PositiveBenzinga•Oct 17, 2025, 04:20 PM
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $153
📈 PositiveBenzinga•Oct 17, 2025, 02:20 PM
Disc Medicine To Present Clinical Data From Its Phase 1b Trial Of DISC-0974 At Upcoming 2025 American Society Of Nephrology Kidney Week In Houston, Texas, From November 6–9, 2025
📈 PositiveBenzinga•Oct 17, 2025, 01:04 PM
Disc Medicine shares are trading higher after the company announced that it received a Commissioner's National Priority Voucher from the FDA for bitopertin in erythropoietic protoporphyria, including X-linked protoporphyria. Wedbush maintained an Outperform rating on the stock and raised its price target from $90 to $110.
📈 PositiveBenzinga•Oct 17, 2025, 12:51 PM
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110
📈 PositiveBenzinga•Oct 17, 2025, 12:31 PM
Disc Medicine Receives FDA Commissioner's National Priority Voucher For Bitopertin in Erythropoietic Protoporphyria; Disc Is Seeking Accelerated Approval Of Bitopertin For Patients Aged 12 Years And Older With EPP; The CNPV Program Is Designed To Reduce The Drug Application Review Process To 1-2 Months
📈 PositiveBenzinga•Oct 16, 2025, 09:39 PM
Disc Medicine Submits New Drug Application To FDA For Accelerated Approval Of Bitopertin For Patients With Erythropoietic Protoporphyria
📈 PositiveBenzinga•Sep 30, 2025, 12:34 PM
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $90
📈 PositiveBenzinga•Aug 18, 2025, 01:19 PM
Frequently Asked Questions about IRON
What is IRON's current stock price?
Disc Medicine, Inc. (IRON) is currently trading at $80.04 per share. The stock has moved -11.50% today.
What is the analyst price target for IRON?
The average analyst price target for IRON is $120.40, based on 1 analyst.
What sector is Disc Medicine, Inc. in?
Disc Medicine, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IRON's market cap?
Disc Medicine, Inc. has a market capitalization of $3.02 billion, making it a mid-cap company.
Does IRON pay dividends?
No, Disc Medicine, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
ADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to IRON for comparison